Please assess the completion status of the following clinical trial:

Trial Title: Exercise and Metformin in Colorectal and Breast Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed stage I-III colorectal or breast cancer~* Undergone curative-intent complete surgical resection and completed all adjuvant therapy (if indicated) at least 2 months prior to enrollment~* Note: Breast cancer subjects on hormonal therapy or trastuzumab only therapy and colorectal cancer subjects on adjunctive therapies not considered cytotoxic chemotherapy (including those participating in CALGB 80702 receiving only celecoxib/placebo) are eligible.~* Participants will be allowed to receive concomitant adjuvant endocrine therapy for breast cancer; however, all endocrine agents must be initiated at least 1 month prior to enrollment in the study and continued throughout the duration of study participation.~* Less than 120 minutes of exercise per week~* Approval by oncologist or surgeon~* English speaking and able to read English~* No planned surgery anticipated in the 3 month intervention period~* At least one month from any major surgery to start of intervention including colostomy reversal~Exclusion Criteria:~* Concurrent other malignancy or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer or in-situ cervical cancer)~* Metastatic disease~* Scheduled to receive any form of further adjuvant cancer therapy~* Currently on medication for diabetes treatment~* Pregnant or breast-feeding~* Any condition associated with increased risk of metformin-associated lactic acidosis (prior renal failure or liver failure, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)~* Known hypersensitivity or intolerance to metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exercise training (Type: ACTIVE_COMPARATOR): Exercise training with exercise physiologist
- Exercise training with metformin (Type: ACTIVE_COMPARATOR): Exercise training with exercise physiologist with oral metformin
- Metformin (Type: ACTIVE_COMPARATOR): Metformin
- Control (Type: ACTIVE_COMPARATOR): Educational information

Based on this trial design, predict the completion outcome and termination type (if applicable).